In the future, NGS will have a greater impact on CDM, as targeted treatment options for CCA and pancreatic carcinoma expand, including US Food and Drug Administration-approved options for mutations in theFGFRpathway,IDH1,ERBB2,BRCA1/2, and microsatellite-instable tumors. This evidence concerns the gene IDH1 and cholangiocarcinoma.